Volume 29, Issue 4 (December 2025)                   Physiol Pharmacol 2025, 29(4): 484-491 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Farhangi S, sheibani V, Javan M. Targeting of demyelinated lesions in experimental models of multiple sclerosis using a fibrin binding peptide. Physiol Pharmacol 2025; 29 (4) :484-491
URL: http://ppj.phypha.ir/article-1-2338-en.html
Targeting of demyelinated lesions in experimental models of multiple sclerosis using a fibrin binding peptide
Sahar Farhangi , Vahid Sheibani , Mohammad Javan
Abstract:   (1893 Views)

Introduction: Multiple sclerosis (MS) is an autoimmune and inflammatory disease of the central nervous system characterized by demyelination, astrogliosis, blood-brain barrier (BBB) disruption, and axonal damage. Currently available clinical and experimental approaches for MS are not completely effective because of the inability to pass the BBB, off-target distribution, and the need to increase the dosage. It has been shown that BBB disruption and fibrin deposition occur in the region of lesions in MS. Coagulation factor XIII binds to fibrin through the heptapeptide NQEQVSP in its structure. Here, NQEQVSP was used to target the lesions in animal models of MS. Methods: Microglia, astrocytes, and oligodendrocytes were immuno- stained using antibodies against Iba1, GFAP, and MBP, respectively.
Results: We showed that peptide NQEQVSP binding was specific to the lesion sites induced by lysophosphatidylcholine (LPC) injection into the corpora callosa of mice. The peptide was FAM labeled, and its co-localization with different glial cells was evaluated. Co-localization was mainly detected with the microglia in the damaged area. A lower level of co-localization was also observed for oligodendrocytes.
Conclusion: Our results promise the possibility of using NQEQVSP peptide to target the lesions for specific drug delivery in patients suffering from multiple sclerosis.

Keywords: Targeting Peptide, Fibrin, Targeted delivery, Glial cells, Multiple sclerosis
Full-Text [PDF 2197 kb]   (25 Downloads)    
Type of Manuscript: Experimental research article | Subject: Neurophysiology/Pharmacology
References
1. Absinta M, Lassmann H, Trapp B. Mechanisms underlying progression in multiple sclerosis. Current Opinion in Neurology 2020; 33: 277-277. [DOI:10.1097/WCO.0000000000000818]
2. Adams R A, Passino M, Sachs B D, Nuriel T, Akassoglou K. Fibrin mechanisms and functions in nervous system pathology. Molecular Interventions 2004; 4: 163-163.
3. Aguilar Z. Nanomaterials for medical applications: Newnes, 2012.
4. Davalos D, Kyu Ryu J, Merlini M, Baeten K M, Le Moan N, Petersen M A, et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nature Communications 2012; 3: 1-15. [DOI:10.1038/ncomms2230]
5. Farhangi S, Dehghan S, Totonchi M, Javan M. In vivo conversion of astrocytes to oligodendrocyte lineage cells in adult mice demyelinated brains by Sox2. Multiple Sclerosis and Related Disorders 2019; 28: 263-272. [DOI:10.1016/j.msard.2018.12.041]
6. Farhangi S, Karimi E, Khajeh K, Hosseinkhani S, Javan M. Peptide mediated targeted delivery of gold nanoparticles into the demyelination site ameliorates myelin impairment and gliosis. Nanomedicine: Nanotechnology, Biology and Medicine 2023; 47: 102609-102609. [DOI:10.1016/j.nano.2022.102609]
7. Ford H. Clinical presentation and diagnosis of multiple sclerosis. Clinical Medicine 2020; 20: 380-380. [DOI:10.7861/clinmed.2020-0292]
8. Goldenberg M M. Multiple sclerosis review. Pharmacy and Therapeutics 2012; 37: 175-175.
9. Hammond T R, Gadea A, Dupree J, Kerninon C, Nait-Oumesmar B, Aguirre A, et al. Astrocyte-derived endothelin-1 inhibits remyelination through notch activation. Neuron 2014; 81: 588-602. [DOI:10.1016/j.neuron.2014.03.007]
10. Inoue A, Koh C-S, Yamazaki M, Yanagisawa N, Ishihara Y, Kim B S. Fibrin deposition in the central nervous system correlates with the degree of Theiler's murine encephalomyelitis virus-induced demyelinating disease. Journal of Neuroimmunology 1997; 77: 185-194. [DOI:10.1016/S0165-5728(97)00072-6]
11. Jiang Z, Guan J, Qian J, Zhan C. Peptide ligand-mediated targeted drug delivery of nanomedicines. Biomaterials Science 2019; 7: 461-471. [DOI:10.1039/C8BM01340C]
12. Kamma E, Lasisi W, Libner C, Ng H S, Plemel J R. Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics. Journal of Neuroinflammation 2022; 19: 1-27. [DOI:10.1186/s12974-022-02408-y]
13. Ponath G, Park C, Pitt D. The role of astrocytes in multiple sclerosis. Frontiers in Immunology 2018; 9: 217-217. [DOI:10.3389/fimmu.2018.00217]
14. Pourabdolhossein F, Mozafari S, Morvan-Dubois G, Mirnajafi-Zadeh J, Lopez-Juarez A, Pierre-Simons J, et al. Nogo receptor inhibition enhances functional recovery following lysolecithin-induced demyelination in mouse optic chiasm. PloS One 2014; 9: e106378-e106378. [DOI:10.1371/journal.pone.0106378]
15. Ryu J K, Petersen M A, Murray S G, Baeten K M, Meyer-Franke A, Chan J P, et al. Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation. Nature Communications 2015; 6: 1-15. [DOI:10.1038/ncomms9164]
16. Schense J C, Bloch J, Aebischer P, Hubbell J A. Enzymatic incorporation of bioactive peptides into fibrin matrices enhances neurite extension. Nature Biotechnology 2000; 18: 415-419. [DOI:10.1038/74473]
17. Schirmer L, Schafer D P, Bartels T, Rowitch D H, Calabresi P A. Diversity and function of glial cell types in multiple sclerosis. Trends in Immunology 2021; 42: 228-247. [DOI:10.1016/j.it.2021.01.005]
18. Seyedsadr M S, Weinmann O, Amorim A, Ineichen B V, Egger M, Mirnajafi-Zadeh J, et al. Inactivation of sphingosine-1-phosphate receptor 2 (S1PR2) decreases demyelination and enhances remyelination in animal models of multiple sclerosis. Neurobiology of Disease 2019; 124: 189-201. [DOI:10.1016/j.nbd.2018.11.018]
19. Wang Y, Cheng X, He Q, Zheng Y, Kim D H, Whittemore S R, et al. Astrocytes from the contused spinal cord inhibit oligodendrocyte differentiation of adult oligodendrocyte precursor cells by increasing the expression of bone morphogenetic proteins. Journal of Neuroscience 2011; 31: 6053-6058. [DOI:10.1523/JNEUROSCI.5524-09.2011]
20. Zhan J, Mann T, Joost S, Behrangi N, Frank M, Kipp M. The cuprizone model: dos and do nots. Cells 2020; 9: 843-843. [DOI:10.3390/cells9040843]
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.